Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Reyskens Dairy LLC
WARNING LETTER
•Reyskens Dairy LLC•November 19, 2013

FDA WARNING_LETTER - Reyskens Dairy LLC - November 19, 2013

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

The FDA issued a Warning Letter to Reyskens Dairy, LLC following a November 19, 2013, investigation of their Custer, Ohio, dairy operation. The letter details multiple violations of the Federal Food, Drug, and Cosmetic Act. A key finding was the sale of an adulterated dairy cow for slaughter, with kidney tissue containing 0.89 ppm of desfuroylceftiofur, exceeding the 0.4 ppm tolerance (21 C.F.R. 556.113(b)(3)(i)), rendering the food adulterated under section 402(a)(2)(C)(ii).

The investigation also revealed that animals were held under inadequate conditions, increasing the likelihood of medicated animals with harmful drug residues entering the food supply, exemplified by a failure to maintain complete treatment records, violating section 402(a)(4). Furthermore, the firm adulterated the drug Excede by using it extra-label, not as directed by its approved labeling. This extra-label use was not under veterinarian supervision (21 C.F.R. 530.11(a)) and resulted in illegal drug residue (21 C.F.R. 530.11(d)), causing the drug to be unsafe and adulterated under sections 512(a) and 501(a)(5).

Reyskens Dairy is required to take prompt corrective action and establish preventative procedures. A written response detailing these steps, including documentation, is due within fifteen working days. Failure to comply may lead to further regulatory actions like seizure or injunction.

Company
Reyskens Dairy LLC
Inspection Date
November 19, 2013
Product Type
Drugs
Office
Cincinnati District Office
Person
  • Paul J. Teitell (District Director)
Open in Dashboard

ID · 77a63216-37d3-41fc-b789-e7ba2002b01e

Violation Codes10
21 U.S.C. 342(a)(2)(C)(ii)21 U.S.C. 360b21 U.S.C. 342(a)(4)21 CFR 556.113(b)(3)(i)21 CFR 530.3(a)21 U.S.C. 360b(a)(4)21 U.S.C. 360b(a)(5)21 CFR 53021 CFR 530.11(a)21 CFR 530.11(d)

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.